



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 22, 2024

Robert Hershberg
Chief Executive Officer
HilleVax, Inc.
321 Harrison Avenue
Boston, MA 02118

Re: HilleVax, Inc.
Registration Statement on Form S-3
Filed March 20, 2024
File No. 333-278110

Dear Robert Hershberg:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Cheston Larson